DWA
ROIV icon

Dorsey Wright & Associates’s Roivant Sciences ROIV Stock Holding History

Dorsey Wright & Associates’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.9M Sell
391,662
-185,485
-32% -$5.48M 2.35% 7
2026
Q1 		$16M Buy
577,147
+201,041
+53% +$5.16M 1.98% 13
2025
Q4 		$8.16M Buy
+376,106
New +$7.42M 1.76% 14

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Dorsey Wright & Associates's ROIV Position: Q2 2026 in Review

Dorsey Wright & Associates reduced its Roivant Sciences (ROIV) stake by 32% in Q2 2026, selling an estimated $5.48M and leaving 391,662 shares worth $13.9M. The position accounts for 2.35% of the portfolio, ranked #7.

Dorsey Wright & Associates first reported a position in ROIV in Q4 2025 and has held it in 3 quarters since. The position peaked at $16M in Q1 2026. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

  • Dorsey Wright & Associates held 391,662 shares of Roivant Sciences worth $13.9M as of Q2 2026.
  • Dorsey Wright & Associates sold 185,485 Roivant Sciences shares in Q2 2026, an estimated $5.48M.
  • Roivant Sciences made up 2.35% of Dorsey Wright & Associates's portfolio in Q2 2026, its #7 holding.
  • Dorsey Wright & Associates first reported a position in Roivant Sciences in Q4 2025 and has held it in 3 quarters since.
  • Dorsey Wright & Associates's Roivant Sciences position peaked at $16M in Q1 2026.
  • 498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Dorsey Wright & Associates's 13F filing for Q2 2026, filed 6 Aug 2026.